Confronto
LL-37 vs. Oxytocin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
597562-32-8
50-56-6
Peso molecolare
4493.33 g/mol
1007.19 g/mol
Emivita
nessun dato
0.05 h
Sequenza
LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESCys-Tyr-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2Meccanismo d'azione
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Oxytocin
Oxytocin is synthesised in the hypothalamus and released via the posterior pituitary. Peripherally it binds the oxytocin receptor, a G-protein-coupled receptor, and through the phospholipase-C cascade and calcium release triggers contraction of uterine smooth muscle and milk ejection — the pharmacological basis of the obstetric approval. Centrally, oxytocin acts as a neuromodulator and has been linked to social bonding, trust and modulation of stress and anxiety circuits. Its central effects in humans are mechanistically incompletely understood, particularly because it is unclear to what extent peripherally or intranasally administered oxytocin crosses the blood-brain barrier.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
4
di cui sull'uomo
1
4
Effetti registrati
4
3
Contraddizioni aperte
1
1
Eventi avversi documentati
0
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between LL-37 and Oxytocin?
- LL-37 is classified as "Ricerca (altro)", while Oxytocin is classified as "Ricerca (altro)". LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. Oxytocin: Oxytocin is an endogenous nonapeptide hormone of the posterior pituitary. In synthetic form (Pitocin, Syntocinon) it has been approved for decades to induce and augment labour and to control postpartum uterine bleeding. Strictly separate from this is intranasal use to influence social behaviour, trust, anxiety or autism symptoms: this use is unapproved, purely experimental, and yields inconsistent and often negative results in controlled trials. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, LL-37 or Oxytocin?
- The highest available evidence level is "Studio sull'uomo" for LL-37 and "RCT sull'uomo" for Oxytocin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of LL-37 and Oxytocin in Germany and the United States?
- Germania: LL-37 — Solo ricerca, Oxytocin — Su prescrizione. Stati Uniti: LL-37 — Solo ricerca, Oxytocin — Su prescrizione. These are factual summaries with source and review date on the individual pages.